(Q53350069)

13 May 2018

title

Summary of the II International Symposium on Cytomegalovirus. (English)

1 reference

13 May 2018

0 references

M D de Jong

1

1 reference

13 May 2018

G J Galasso

2

1 reference

13 May 2018

B Gazzard

3

1 reference

13 May 2018

P D Griffiths

4

1 reference

13 May 2018

D A Jabs

5

1 reference

13 May 2018

E R Kern

6

1 reference

13 May 2018

S A Spector

7

1 reference

13 May 2018

publication date

1 October 1998

1 reference

13 May 2018

published in

Antiviral Research

1 reference

13 May 2018

volume

39

1 reference

13 May 2018

issue

3

1 reference

13 May 2018

page(s)

141-162

1 reference

13 May 2018

Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

The role of antibody concentration and avidity in antiviral protection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recov

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus in peripheral blood leukocytes of infants with congenital or postnatal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Magnetic resonance imaging of the brain in congenital cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Virus-specific antibody responses to human cytomegalovirus (HCMV) in human immunodeficiency virus type 1-infected persons with HCMV retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus infection and reinfection transmitted by heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Interrelationships among Quantity of Human Cytomegalovirus (HCMV) DNA in Blood, Donor‐Recipient Serostatus, and Administration of Methylprednisolone as Risk Factors for HCMV Disease following Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis S

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Maternal age and congenital cytomegalovirus infection: screening of two diverse newborn populations, 1980-1990

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus preemptive therapy with ganciclovir in renal transplant patients treated with OKT3

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Prophylaxis against CMV infection in transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

The Effect of Valaciclovir on Cytomegalovirus Viremia and Viruria Detected by Polymerase Chain Reaction in Patients with Advanced Human Immunodeficiency Virus Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Once-weekly intraocular injections of ganciclovir for maintenance therapy of cytomegalovirus retinitis: clinical and ocular outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Monitoring of renal allograft recipients by quantitation of human cytomegalovirus genomes in peripheral blood leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Quantitative cytomegalovirus (CMV) antigenaemia during antiviral treatment of AIDS-related CMV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Serum Polymerase Chain Reaction for Cytomegalovirus DNA for Monitoring Ganciclovir Treatment in AIDS Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Ganciclovir implant exchange. Timing, surgical procedure, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Pneumonitis in bone marrow transplant recipients results from a local immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

T cell therapy of human CMV and EBV infection in immunocompromised hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Preemptive Therapy in Immunocompromised Hosts

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Antimicrobial strategies in the care of organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Comparative Serial Virologic and Serologic Studies of Symptomatic and Subclinical Congenitally and Natally Acquired Cytomegalovirus Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Late intrauterine Cytomegalovirus infection: clinical and neuroimaging findings

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Magnetic resonance imaging of the brain in congenital rubella virus and cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (Macaca mulatta).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Intravitreal and systemic foscarnet in the treatment of AIDS-related CMV retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2898%2900044-8

7 January 2021

10.1016/S0166-3542(98)00044-8

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018